US FDA Advisory Committees' Future: Drug-Agnostic Panels, More Debate Time

 
• By Sarah Karlin-Smith
boats
The FDA is looking to “float all boats” with future non-drug specific advisory panel topics. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers